1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
China Pharma Holdings, Inc.

China Pharma Holdings, Inc.

CPHI
China Pharma Holdings, Inc.US flagNew York Stock Exchange Arca
0.82
USD
-0.02
- -
33.23MMarket Cap

Total Valuation

China Pharma Holdings, Inc. carries a market capitalization of 33.23M, placing it among publicly traded companies globally. Its enterprise value stands at 30.50M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap33.23M
Enterprise Value30.50M

Share Statistics

China Pharma Holdings, Inc. currently has 40.52M shares outstanding.

Shares Outstanding40.52M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 3.93, and the price-to-book ratio stands at 0.74.

PE RatioN/A
PS Ratio3.93
PB Ratio0.74
P/TBV Ratio-10.41
P/FCF Ratio-163.63
P/OCF Ratio-109.63

Enterprise Valuation

EV / Sales7.79
EV / EBITDAN/A
EV / EBITN/A
EV / FCF6,205.47

Financial Position

China Pharma Holdings, Inc. maintains a current ratio of 0.26, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 11.21, indicating elevated leverage, while an interest coverage ratio of -13.38 demonstrates limited ability to service its debt obligations.

Current Ratio0.26
Quick Ratio0.07
Debt / Equity11.21
Debt / EBITDA-3.06
Interest Coverage-13.38

Financial Efficiency

Return on Equity (ROE)-20.99
Return on Assets (ROA)-15.30
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover2.27

Stock Price Statistics

China Pharma Holdings, Inc.'s stock has declined approximately -51.1875% over the past 52 weeks. The 50-day moving average sits at 1.14, while the 200-day moving average is 0.98.

Beta (5Y)N/A
52-Week Price Change-51.1875%
50-Day Moving Average1.14
200-Day Moving Average0.98
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, China Pharma Holdings, Inc. generated 3.91M in revenue and converted that into -4.47M in net income, yielding earnings per share of -0.19. EBITDA reached -1.33M, while operating income came in at -4.38M.

Revenue3.91M
Gross Profit460,174.00
Operating Income-4.38M
Pretax Income-4.47M
Net Income-4.47M
EBITDA-1.33M
EBIT-4.38M
Earnings Per Share (EPS)-0.19

Balance Sheet

China Pharma Holdings, Inc. holds 304,874.00 in cash and equivalents against 4.06M in total debt, resulting in a net debt position of 3.60M. Total book value stands at 36.18M, with working capital of -5.67M providing operational flexibility.

Cash & Cash Equivalents304,874.00
Total Debt4.06M
Net Debt3.60M
Equity (Book Value)36.18M
Book Value Per Share0.89
Working Capital-5.67M

Cash Flow

China Pharma Holdings, Inc. produced -140,490.00 in operating cash flow over the past twelve months. After subtracting -46,365.00 in capital expenditures, free cash flow totaled -186,855.00 - equivalent to -0.01 per share.

Operating Cash Flow-140,490.00
Capital Expenditures-46,365.00
Free Cash Flow-186,855.00
FCF Per Share-0.01

Margins

China Pharma Holdings, Inc. operates with a gross margin of 11.76, reflecting its pricing power and cost economics. The operating margin of -111.84 and net profit margin of -114.33 provide insight into operational efficiency.

Gross Margin11.76
Operating Margin-111.84
Pretax Margin-114.33
Profit Margin-114.33
EBITDA Margin-33.86

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield0.58
FCF Yield-0.61

Stock Splits

China Pharma Holdings, Inc.'s most recent stock split took place on April 15, 2025 with a 10:1 split ratio.

Last Split Date4/15/2025
Split Ratio10:1

Scores

China Pharma Holdings, Inc. posts an Altman Z-Score of -12.73, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-12.73